Recombinant varicella-zoster virus glycoprotein E antigen vaccine

Generic Medicine Info
Indications and Dosage
Prevention of herpes zoster
Adult: ≥18 years (who are or will be immunodeficient or immunosuppressed): 2 doses of 0.5 mL each given at Month 0 followed by a 2nd dose 1-2 months later. ≥50 years (immunocompetent individuals): 2 doses of 0.5 mL each given at Month 0 followed by a 2nd dose 2-6 months later.
Withdraw the entire contents of the vial containing the supplied adjuvant suspension and slowly add into to the vial containing the powder. Swirl gently until the powder is completely dissolved. Do not shake vigorously.
Severe hypersensitivity (e.g. anaphylaxis).
Special Precautions
Patient with current or recent febrile illness, thrombocytopenia or any coagulation disorder Not indicated for the treatment of active zoster symptoms or postherpetic neuralgia and prevention of primary varicella infection (chickenpox). Delay vaccination in pregnant women.
Adverse Reactions
Significant: Syncope (may be accompanied by transient neurological signs e.g. visual disturbance, paraesthesia, and tonic-clonic limb movements), shoulder injury (e.g. shoulder bursitis or tendinopathy), increased risk of Guillain-Barré syndrome.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Fever, fatigue, chills, malaise, inj site reactions (e.g. pain, redness, swelling, pruritus).
Musculoskeletal and connective tissue disorders: Myalgia.
Nervous system disorders: Headache.
Potentially Fatal: Anaphylactoid/hypersensitivity reactions.
Monitoring Parameters
Monitor for anaphylaxis and syncope for 15 minutes following administration.
Drug Interactions
Immunosuppressive agents may reduce the effectiveness of the vaccine.
Mechanism of Action: Recombinant varicella-zoster glycoprotein E antigen vaccine is an inactivated zoster vaccine containing recombinant varicella-zoster virus (VZV) surface glycoprotein E (gE) antigen and an adjuvant (i.e. AS01B). Non-clinical data show that AS01B) induces a local and transient activation of the innate immune system via specific molecular pathways. This facilitates the recruitment and activation of antigen presenting cells carrying gE-derived antigens in the draining lymph node, leading to the generation of gE-specific CD4+ T cells and antibodies.
Synonyms: recombinant zoster vaccine (RZV); herpes zoster vaccine (recombinant, adjuvanted).
Store between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Vaccines, Antisera & Immunologicals
Anon. Zoster Vaccine (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 01/12/2021.

Anon. Zoster Vaccine Recombinant. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 01/12/2021.

Shingrix (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. Accessed 01/12/2021.

Shingrix (GSK Group of Companies). MIMS Hong Kong. Accessed 01/12/2021.

Shingrix Powder and Suspension for Suspension for Injection (GlaxoSmithKline Biologicals S.A). European Medicines Agency [online]. Accessed 01/12/2021.

Shingrix Suspension for Intramuscular Injection (GlaxoSmithKline Biologicals). U.S. FDA. Accessed 01/12/2021.

Disclaimer: This information is independently developed by MIMS based on Recombinant varicella-zoster virus glycoprotein E antigen vaccine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in